Gamma delta T-cell immunotherapy - Beijing Doing BiomedicalAlternative Names: γδ T-cell immunotherapy
Latest Information Update: 30 Nov 2015
At a glance
- Originator Beijing Doing Biomedical
- Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastric cancer
Most Recent Events
- 30 Nov 2015 Preclinical trials in Gastric cancer in China (unspecified route)
- 30 Nov 2015 Beijing Doing Biomedical plans a phase I/II trial for Gastric cancer in China (NCT02585908)